FindTrial
Sign In

PAN INDIA Genetics Study of MODY

"Comprehensive genetic screening for maturity onset diabetes of the young (MODY): A PAN INDIA STUDY

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/12/022394
Enrollment
47
Registered
2019-12-17
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E138- Other specified diabetes mellituswith unspecified complications

Interventions

Intervention1: GLICLAZIDE (DIAMICRON MR 60): Gliclazide EXTENDED RELEASE 60mg (DIAMICRON�® XR 60), orally, once or twice daily

Sponsors

Dr V Mohan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age of onset of diabetes of the proband between 7-30 years 2. Body mass index below 30kg/m2 3. Family history of diabetes in one or both parents of the proband. 4. Duration of diabetes less than 2 years 5. Patients who understand the nature of study and willing to provide a written informed consent 6. Good pancreatic B- cell reserve as shown by C- peptide levels 7. GAD and / or Zinc Transporter or IA-2 antibodies negative.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Gestational diabetes 3. Fibrocalculous pancreatic diabetes 4. Presence of acanthosis nigricans or severe obesity

Design outcomes

Primary

MeasureTime frame
This study is expected to delineate the prevalence of MODY and its subtypes in India. This study will also help to compare DNA obtained from salivary samples with DNA obtained from blood in the same individuals and this help to standardize the salivary methods for MODY (monogenic diabetes) detection in the future. The study will provide data on the efficacy and safety of (Diamicron MR 60) in the MODY subtypes 1, 3 and 12. It will help to increase awareness about MODY in India. Timepoint: June 2021—

Secondary

MeasureTime frame
This study will also help to compare DNA obtained from salivary samples with DNA obtained from blood in the same individuals and this help to standardize the salivary methods for MODY (monogenic diabetes) detection in the future. The study will provide data on the efficacy and safety of (Diamicron MR 60) in the MODY subtypes 1, 3 and 12. It will help to increase awareness about MODY in India. Timepoint: June 2021—

Countries

India

Contacts

Public ContactDr V Mohan

Madras Diabetes Research Foundation

drmohans@diabetes.ind.in04443968888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026